RAPP
Rapport Therapeutics, Inc. Common Stock NASDAQ Listed Jun 7, 2024$37.06
After hrs
$36.34
-1.94%
Mkt Cap $1.4B
52w Low $7.73
84.9% of range
52w High $42.27
50d MA $31.83
200d MA $26.48
P/E (TTM)
-11.8x
EV/EBITDA
-11.2x
P/B
3.3x
Debt/Equity
0.0x
ROE
-23.0%
P/FCF
-16.2x
RSI (14)
—
ATR (14)
—
Beta
1.10
50d MA
$31.83
200d MA
$26.48
Avg Volume
332.4K
About
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs wi…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 10, 2026 | AMC | -0.65 | -0.72 | -10.8% | 29.63 | +0.8% | +3.1% | -3.2% | -6.0% | -6.8% | -6.4% | — |
| Nov 6, 2025 | AMC | -0.77 | -0.71 | +7.8% | 25.36 | +4.3% | +1.2% | -1.7% | +0.6% | -0.7% | -2.7% | — |
| Aug 7, 2025 | AMC | -0.87 | -0.75 | +13.8% | 15.41 | +0.0% | -5.6% | -7.3% | +0.8% | +1.2% | -3.0% | — |
| May 8, 2025 | AMC | -0.77 | -0.68 | +11.7% | 10.65 | -0.2% | -3.8% | -1.7% | -6.2% | -9.6% | -8.4% | — |
| Mar 11, 2025 | AMC | -0.62 | -0.57 | +8.1% | 8.96 | +5.4% | +11.7% | +11.8% | +17.3% | +13.6% | +10.8% | — |
| Nov 7, 2024 | AMC | -0.57 | -0.50 | +12.3% | 26.90 | +0.0% | -0.8% | +0.0% | -9.8% | -18.8% | -18.3% | — |
| Aug 8, 2024 | AMC | -0.68 | -1.70 | -150.0% | 18.56 | -4.4% | +2.7% | -1.6% | +9.7% | +9.9% | +9.8% | — |
| Mar 31, 2024 | AMC | — | -0.12 | — | — | — | — | — | — | — | — | — |
| Dec 31, 2023 | AMC | — | -0.07 | — | — | — | — | — | — | — | — | — |
| Sep 30, 2023 | AMC | — | -0.05 | — | — | — | — | — | — | — | — | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 22 | BTIG | Maintains | Buy → Buy | — | $36.95 | $37.38 | +1.2% | -0.5% | -1.6% | -1.1% | -4.2% | -8.7% |
| Mar 11 | BTIG | Maintains | Buy → Buy | — | $29.63 | $29.86 | +0.8% | +3.1% | -3.2% | -6.0% | -6.8% | -6.4% |
| Mar 11 | Wells Fargo | Maintains | Overweight → Overweight | — | $29.63 | $29.86 | +0.8% | +3.1% | -3.2% | -6.0% | -6.8% | -6.4% |
| Dec 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $30.16 | $30.68 | +1.7% | -5.0% | -4.9% | -4.6% | +0.4% | -1.9% |
| Dec 8 | BTIG | Maintains | Buy → Buy | — | $29.50 | $30.18 | +2.3% | +2.2% | -2.9% | -2.8% | -2.4% | +2.6% |
| Nov 7 | Citizens | Maintains | Market Outperform → Market Outperform | — | $25.36 | $26.46 | +4.3% | +1.2% | -1.7% | +0.6% | -0.7% | -2.7% |
| Sep 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.36 | $38.42 | +167.5% | +119.2% | +95.2% | +56.0% | +61.6% | +65.5% |
| Jul 8 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $12.04 | $12.04 | +0.0% | +4.8% | +16.4% | +27.7% | +21.3% | +21.5% |
Recent Filings
8-K · 8.01
!! High
Rapport Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Rapport Therapeutics announced positive Phase 2a data for RAP-219 in focal onset seizures, showing the drug reduced long episodes—an objective biomarker with 90% concordance to clinical seizures—supporting further development.
Apr 21
8-K
Unknown — 8-K Filing
Rapport's $490.5 million cash runway extending to mid-2029 provides sufficient capital for RAP-219 development across multiple indications, reducing near-term financing risk and allowing investors to evaluate clinical progress before potential dilution.
Mar 10
Data updated apr 26, 2026 9:53pm
· Source: massive.com